RxDoctor Payments Data

Sean Green, APRN

Family · Mechanicsville, VANPI 1902850936

Payments from drug & device makers

$5,654in general payments, 2019–2025

Across 331 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$745
  • AbbVie$576
  • Lilly USA, LLC$342
  • Bayer$276
  • Otsuka America Pharmaceutical, Inc.$249
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,635100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,654 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$101,127
Medicare patients
332
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate95$133,910
EliquisApixaban66$81,620
JardianceEmpagliflozin31$49,302
XifaxanRifaximin12$44,701
MounjaroTirzepatide30$36,322
OzempicSemaglutide26$35,969
XareltoRivaroxaban25$35,800
TrulicityDulaglutide20$31,774
UbrelvyUbrogepant15$24,256
MyrbetriqMirabegron25$23,721
JanumetSitagliptin Phos/Metformin Hcl18$18,935
FarxigaDapagliflozin Propanediol11$13,623
Tresiba Flextouch U-100Insulin Degludec27$11,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,388
Spiriva HandihalerTiotropium Bromide13$6,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$103$152,845113 claims
PfizerEliquis$152$81,62066 claims
Lilly USA, LLCMounjaro, Trulicity$342$68,09750 claims
Boehringer IngelheimJardiance$186$49,30231 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$163$44,70112 claims
Novo NordiskOzempic$1,278$35,96926 claims
Johnson & JohnsonXarelto$112$35,80025 claims
AbbVieUbrelvy$576$24,25615 claims
AstraZenecaFarxiga$104$13,62311 claims
GSKTrelegy Ellipta$80$11,38818 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$4,289373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →